




Searching News Database: Ipsen
HSMN NewsFeed - 3 May 2021
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
HSMN NewsFeed - 16 May 2018
Photocure Announces Blue Light Cystoscopy with Cysview(R) Now Available for Surveillance of Bladder Cancer
Photocure Announces Blue Light Cystoscopy with Cysview(R) Now Available for Surveillance of Bladder Cancer
HSMN NewsFeed - 21 Jul 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
HSMN NewsFeed - 22 Jan 2016
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
HSMN NewsFeed - 5 Nov 2014
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
HSMN NewsFeed - 10 Oct 2014
Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer
Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer
HSMN NewsFeed - 10 Jan 2014
Jonathan Barnsley Joins Ipsen as Executive Vice President, Technical Operations
Jonathan Barnsley Joins Ipsen as Executive Vice President, Technical Operations
HSMN NewsFeed - 14 Jun 2013
Ipsen Reorganizes Its US Neurology Platform and Confirms Its Goal to Become Profitable in the US in 2014
Ipsen Reorganizes Its US Neurology Platform and Confirms Its Goal to Become Profitable in the US in 2014
HSMN NewsFeed - 24 Jan 2013
Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
HSMN NewsFeed - 18 Sep 2012
Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
HSMN NewsFeed - 21 Aug 2012
Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
HSMN NewsFeed - 13 Jun 2012
Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
HSMN NewsFeed - 16 Dec 2011
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing
HSMN NewsFeed - 11 Oct 2011
Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
HSMN NewsFeed - 17 May 2011
Former Pharma Executive, Dr. Dominique Bridon, Joins Optivia Senior Management
Former Pharma Executive, Dr. Dominique Bridon, Joins Optivia Senior Management
HSMN NewsFeed - 21 Sep 2009
AZZALURE(R) approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
AZZALURE(R) approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
HSMN NewsFeed - 26 Jun 2009
AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
HSMN NewsFeed - 31 Mar 2009
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
HSMN NewsFeed - 12 Mar 2009
Ipsen: AZZALURE Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
Ipsen: AZZALURE Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
HSMN NewsFeed - 10 Jun 2008
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
HSMN NewsFeed - 22 May 2008
Ipsen: Appointment of Gerard Picot as Vice President, Global Regulatory Affairs
Ipsen: Appointment of Gerard Picot as Vice President, Global Regulatory Affairs
HSMN NewsFeed - 5 May 2008
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
HSMN NewsFeed - 7 Mar 2008
Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
HSMN NewsFeed - 26 Feb 2008
CollaGenex Pharmaceuticals Signs Merger Agreement with Galderma Pharma S.A.
CollaGenex Pharmaceuticals Signs Merger Agreement with Galderma Pharma S.A.
HSMN NewsFeed - 12 Feb 2008
Ipsen: Clinical Update For Decapeptyl(R) 6-Month Formulation in Advanced Prostate Cancer
Ipsen: Clinical Update For Decapeptyl(R) 6-Month Formulation in Advanced Prostate Cancer
HSMN NewsFeed - 31 Jan 2008
Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport(R) in Cervical Dystonia
Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport(R) in Cervical Dystonia
HSMN NewsFeed - 4 Oct 2007
Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
HSMN NewsFeed - 31 Aug 2007
Ipsen: Somatuline(R) Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly
Ipsen: Somatuline(R) Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly
HSMN NewsFeed - 30 Aug 2007
Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
HSMN NewsFeed - 23 Aug 2007
Ipsen Transfers Ginkor Fort(R) Marketing Authorisations To GTF For France, Monaco and Andorra
Ipsen Transfers Ginkor Fort(R) Marketing Authorisations To GTF For France, Monaco and Andorra
HSMN NewsFeed - 12 Jul 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
HSMN NewsFeed - 25 May 2007
Ipsen: Increlex(R) Receives CHMP Positive Opinion for the Treatment of Severe Primary IGF-1 Deficiency
Ipsen: Increlex(R) Receives CHMP Positive Opinion for the Treatment of Severe Primary IGF-1 Deficiency
HSMN NewsFeed - 16 Apr 2007
Ipsen Appoints Sean McKercher as Vice President of Commercial Development in North America
Ipsen Appoints Sean McKercher as Vice President of Commercial Development in North America
HSMN NewsFeed - 10 Apr 2007
GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs
GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs
HSMN NewsFeed - 4 Apr 2007
GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer
GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer
HSMN NewsFeed - 26 Feb 2007
Ipsen: Appointment of Stephane Thiroloix as Executive Vice-President, Corporate Development
Ipsen: Appointment of Stephane Thiroloix as Executive Vice-President, Corporate Development
HSMN NewsFeed - 2 Feb 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
HSMN NewsFeed - 16 Jan 2007
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
HSMN NewsFeed - 15 Jan 2007
FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
HSMN NewsFeed - 2 Nov 2006
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Submitted to FDA
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Submitted to FDA
HSMN NewsFeed - 16 Oct 2006
Ipsen and Tercica Complete Worldwide Strategic Collaboration Agreement in Endocrinology
Ipsen and Tercica Complete Worldwide Strategic Collaboration Agreement in Endocrinology
HSMN NewsFeed - 2 Oct 2006
Ipsen: EMEA's Validation of Febuxostat's Marketing Authorization Application in the European Union
Ipsen: EMEA's Validation of Febuxostat's Marketing Authorization Application in the European Union
HSMN NewsFeed - 7 Sep 2006
GTx and Ipsen Enter Into Partnership Agreement for the European Rights of Acapodene(R)
GTx and Ipsen Enter Into Partnership Agreement for the European Rights of Acapodene(R)
HSMN NewsFeed - 7 Sep 2006
Ipsen and GTx Enter into Partnership Agreement for The European Rights of Acapodene(R)
Ipsen and GTx Enter into Partnership Agreement for The European Rights of Acapodene(R)
Additional items found! 13

Members Archive contains
13 additional stories matching:
Ipsen
(Password required)
Ipsen
(Password required)